Press

Press

2021-04-12 11:00 Kallelse till årsstämma i Acarix AB Regulatory
2021-04-12 11:00 Notice of Annual General Meeting in Acarix AB Regulatory
2021-04-07 10:40 Positive, long term prognostic data from the Dan-NICAD I study published in European Heart Journal- Digital Health
2021-04-07 10:40 Positiva prognostiska långtidsdata från Dan-NICAD 1-studien publiceras i European Heart Journal Digital Health
2021-02-18 08:00 Acarix AB (publ) publicerar Bokslutskommuniké 2020 Regulatory MAR
2021-02-18 08:00 A strong ending of an eventful year Regulatory MAR
2021-01-13 10:00 Positive preliminary data from Acarix’s exploratory heart failure study SEISMO
2021-01-13 10:00 Positiva preliminära data från Acarixs undersökande hjärtsviktstudie SEISMO
2020-12-09 10:15 Acarix announces the last patient included in Dan-NICAD II study
2020-12-09 10:15 Acarix AB meddelar att den sista patienten i Dan-NICAD II studien har inkluderats
2020-11-26 14:23 FDA identifierar unik kod för CADScor® Regulatory MAR
2020-11-26 14:23 FDA identifies exclusive code for the CADScor® Regulatory MAR
2020-11-25 13:15 Acarix erhåller marknadsgodkännande för CADScor® System för försäljning på den amerikanska marknaden Regulatory MAR
2020-11-25 13:15 Acarix receives US market approval for the CADScor® System Regulatory MAR
2020-11-18 09:45 Positiva resultat från Acarix-jämförelseanalys presenterades på den ledande hälsoekonomiska konferensen ISPOR
2020-11-18 09:45 Positive results from Acarix study presented at ISPOR, a leading health economics conference
2020-11-12 13:00 Rättelse: Delårsrapport 2020-01-01 till 2020-09-30 Regulatory MAR
2020-11-12 13:00 Correction: Interim report 2020-01-01 to 2020-09-30 Regulatory MAR
2020-11-12 08:00 En framgångsrik emission med fokus på försäljning! Regulatory MAR
2020-11-12 08:00 A Successful Rights Issue with Focus on Sales! Regulatory MAR
2020-10-15 16:00 Acarix byter Certified Advisor till Redeye
2020-10-15 16:00 Acarix changes Certified Advisor to Redeye
2020-09-29 13:00 Acarix carries out a directed issue of shares to guarantors in conjunction with the oversubscribed rights issue Regulatory
2020-09-29 13:00 Acarix genomför riktad nyemission av aktier till garanter i samband med den övertecknade företrädesemissionen Regulatory
2020-09-28 14:30 Sista dag för handel med BTA Regulatory
2020-09-28 14:30 Last day of trading in paid subscribed shares (Sw. BTA) Regulatory
2020-09-11 13:14 Acarix announce final outcome in oversubscribed rights issue Regulatory
2020-09-11 13:14 Acarix offentliggör slutgiltigt utfall i övertecknad företrädesemission Regulatory
2020-09-09 08:00 Acarix offentliggör preliminärt utfall i övertecknad företrädesemission Regulatory MAR
2020-09-09 08:00 Acarix announces preliminary outcome in oversubscribed rights issue Regulatory MAR
PreviousNext

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based Coronary Artery Disease (CAD) rule-out.

The CE-mark approved and FDA De Novo cleared Acarix CADScor®System is for patients experiencing stable chest pain with suspected CAD and is designed to help reduce millions of unnecessary and costly diagnostic procedures.2 CADScor®System calculates a patient-specific CAD-score non-invasively in 10 minutes with at least 96% confidence (Negative Predictive Value).¹

Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX).

Learn more
  1. User manual US-FDA v.12.Y, prevalence 10,7%
  2. Shaw LJ, Marwick TH, Zoghbi WA, Hundley WG, Kramer CM, Achenbach S, Dilsizian V, Kern MJ, Chandrashekhar Y, Narula J. Why all the focus on cardiac imaging? JACC Cardiovasc Imaging. 2010 Jul;3(7):789-94. doi: 10.1016/j.jcmg.2010.05.004. PMID: 20633864.